IP Library Granted Patent US 10,179,134
Granted Patent B2
US 10,179,134 · App. 14/422,747 · Granted Jan 15, 2019

Polymeric nanoparticles in a thermosensitive gel for coital-independent vaginal prophylaxis of HIV

Inventors: Chris Destache (Omaha, NE); Abhijit Date (Baltimore, MD); Annemarie Shibata (Omaha, NE)
Assignee: Creighton University
A61K31/536A61K9/0036A61K9/06A61K9/5153A61K31/513A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,134
App. No.
14/422,747
Granted
Jan 15, 2019
Kind
B2
Abstract

An antiretroviral composition that gels upon heating and can be administered prophylactically prior to exposure to a retrovirus following sexual intercourse, and methods of using the same.

Claims (9)

1. An antiretroviral composition that can be administered prophylactically up to and including seven days prior to exposure to the retrovirus, the composition comprising:

a mixture of thermosensitive polymers comprising poloxamers including Poloxamers 188 and Poloxamers 407, wherein the ratio of Poloxamers 407 (% weight/volume) to Poloxamer 188 (% weight/volume) in the mixture is about 20:1, and

a nanoparticle comprising a biodegradable polymer and at least one antiretroviral drug,

wherein the composition is a solution at room temperature and is a gel at a temperature between 30° C. and 33° C.

2. The composition of claim 1 , wherein the biodegradable polymer is selected from the group consisting of poly-lactide-co-glycolide, polycaprolactone, cellulose acetate phthalate, or a combination thereof.

3. The composition of claim 1 , wherein the antiretroviral drug is encapsulated within the nanoparticle, directly conjugated to the nanoparticle, indirectly conjugated to the nanoparticle, or a combination thereof.

4. The composition of claim 3 , wherein the antiretroviral drug has a negative log P value at pH 7.4.

5. The composition of claim 3 , wherein the antiretroviral drug has a positive log P value at pH 7.4.

6. The composition of claim 3 , wherein the antiretroviral drug is selected from a group consisting of raltegravir, efavirenz, cellulose acetate phthalate, tenofovir, emtricitabine, and a combination thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 18, 2017
From: CREIGHTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044219/0577 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2015
From: DESTACHE, CHRIS; DATE, ABHIJIT; SHIBATA, ANNEMARIE
To: CREIGHTON UNIVERSITY
Reel/Frame 034991/0025 →
Continuity (2)
Provisional Application 61697083 · Sep 5, 2012
Related Publication 20150190398A1 · Jul 9, 2015